CA 15-3, the most widely used circulating tumour marker in breast cancer patients, is useful in monitoring the response to treatment and gives reliable information on the recurrence of disease (Safi et al, 1989; Dogliotti et al, 1990; Soletormos et al, 1993; Yadav et al, 1993; Gion et al, 1994) . Colomer et al (1989) demonstrated a significant relationship between serum CA 15-3 levels and the overall tumour load in patients with advanced disease. We recently showed (Berruti et al, 1994) that elevated serum CA 15-3 values and visceral metastases are independent variables in predicting overall survival at the time of first relapse of disease. The aim of the present study was to evaluate the relationship between serum CA 15-3 levels and the tumour load at first relapse of disease in predicting survival of metastatic breast cancer patients.
MATERIALS AND METHODS Patients
From October 1988 to March 1995, 312 patients with advanced breast cancer entered the study, of whom 195 were treated and followed at the Servizio di Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Turin, Italy. The remaining 117 patients were recruited from four other institutions involved in a multicentre randomized trial comparing the activity of single-agent epirubicin with epirubicin plus lonidamine (Dogliotti et al, 1996) . All patients were previously submitted to quadrantectomy plus radiation therapy or modified mastectomy when indicated, both associated to axillary node dissection. Adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) was administered in premenopausal patients with lymph node involvement or steroid hormone-negative tumour and in post-menopausal patients with oestrogen receptor (ER)-negative tumour and lymph node invasion. Adjuvant tamoxifen was administered in node-positive post-menopausal patients with hormone-dependent tumours.
Limited locoregional recurrences were treated with radical surgery followed by radiotherapy. The disease extent was defined in accordance with the method proposed by Swenerton et al (1979) and modified by Colomer et al (1989) . In brief, the extent at each site was defined on a four-point scale on which 0 was no disease; 2 minimal involvement; 5 moderate involvement; and 10 extensive involvement. The disease extent was independently evaluated by three investigators who remained blinded from the results of serum CA 15-3 assessment. Final score was determined by the concordance of at least two physicians or by the estimation of more extensive disease. Total burden of metastatic disease was estimated adding the scores of all known disease sites.
Marker assay CA 15-3 serum levels were evaluated by five different laboratories using commercial two-step immunoradiometric assay (IRMA) kits. Serum samples were immediately frozen at -200C after collection and analysed within 15 days. The lowest detection level was 5 U ml-'. Intra-and inter-assay variability was superimposable for the five laboratories and was within 3.5-4% and 6-7% respectively. Inter-laboratory discordance was never greater than 8%. The upper normal concentration was assumed to be 30 U ml-'. (Nie et al, 1988) .
RESULTS

Patient demography
As outlined in Months Figure 1 Overall survival curves of patients according to the disease extent score. Although there are only nine patients with a score more than 15, an advantage in overall survival is evident from patients with a low score through to patients with higher scores. This difference was validated by the log-rank test (P < 0.006) patients (40%) had recurrence within 2 years after mastectomy, and 87 (28%) had initial recurrence in bone, 116 (37%) in lung, 77 (25%) in liver and 32 (10%) in soft tissue. Thirty-three patients (11%) presented with neoplastic pleural effusion, seven (2%) with lymphangitis and three (1%) with abdominal dropsy. Eighty-one patients (26%) had simultaneous recurrence in two metastatic sites, 28 (9%) in three or more. Disease extension according to the Swenerton score was evaluated in 232 patients (74%). Tumour load was not assessable in 41 patients (13%) because of the presence of pleural effusion, lymphangitis or ascites and in the remaining 39 (13%) because of insufficient documentation. The median score for disease extension was 5 (range 2-32). The last follow-up examination was September 1995, when 187 of the 312 patients included (60%) had died. The median time of follow-up from first recurrence of surviving patients was 22.2 months (range 5-107+).
CA 15-3 levels according to site of metastasis and disease extension One hundred and ninety patients out of 312 (61%) had serum CA 15-3 levels above the reference range. CA 15-3 level was more frequently elevated in patients with liver metastases (52 out of 72, 72%) as well as in those presenting with pleural effusion (26 out of 34, 76%) than in patient subgroups with lung (51 out of 81, 63%), bone (46 out of 87, 53%) or skin/lymph node (9 out of 32, 28%) involvement. A total of 117 patients out of 203 (58%) with only one metastatic site had supranormal levels of CA 15-3, whereas elevated marker values were recorded in 53 out of 81 (65%) and 20 out of 28 (71%) of those with two or more disease sites respectively. This increasing trend in CA 15-3 positivity did not attain statistical significance by the Chi-square test (P = 0.1). Conversely, a significant stepwise increase in either CA 15-3 median levels (only considering patients recruited and followed by our institution) or CA 15-3 positivity (including all patients enrolled) with the increase of tumour load has been clearly shown (Table 2) .
Logistic regression analysis showed that the presence of pleural effusion and the disease extent in liver, lung and bone are independent factors in predicting elevated CA 15-3 levels. Conversely, age, menopause, ER status and stage of primary tumour did not enter the model (P < 0.001).
Overall survival evaluation -univariate analyses
The results of the survival analysis of patients grouped according to the different potential prognostic factors one at a time are listed in Table 3 . Survival in patients with visceral metastases was found to be poorer than in those with soft tissue or bone involvement. Liver and skin/lymph node metastases represented the most powerful prognostic factor for short and long survival, respectively, while survival of patients with lung involvement was similar to those with bone metastases. A progressive worsening of survival was found from patients with one site of disease to patients with two or more. Patients with pleural effusion as the single site of disease showed a longer survival than those with lung or bone involvement (data not shown). Other variables such as poor performance status (PS), ER-negative tumour, short DFI were also found to be negatively correlated to overall survival. Elevated levels of CA 15-3 were significantly associated to poor life expectancy in overall patients. Patient stratification according to the disease extent identified at least three subgroups with separate survival curves (Figure 1 ). An inverse correlation between British Journal of Cancer (1997) 75(5), 698-702 I overall survival and both CA 15-3 levels and positivity and disease extent is shown in 
DISCUSSION
This study confirmed the good sensitivity of CA 15-3 in advanced breast cancer patients. Serum marker values significantly correlated with the disease extent, and this strict relationship accounted for the negative prognosis of patients with elevated levels.
The CA 15-3 sensitivity in our series was close to that reported elsewhere (Safi et al, 1989; de Wit et al, 1992; Geraghty et al, 1992; Bombardieri et al, 1993; Hayes, 1993; Soletormos et al, 1993) . We also confirmed the finding (Clark et al, 1987 ) that some initial prognostic characteristics of the primary tumour, such as ER status, remain to be significant for the development of subsequent metastases. As expected, other prognostic factors, such as visceral involvement, DFI, PS, and the number of disease sites have been confirmed to significantly influence overall survival. On the contrary, with respect to the aforementioned study (Clark et al, 1987) , we were unable to demonstrate the negative impact of lymph node involvement at diagnosis, probably because 35% of data were not available.
As repeatedly observed, (Clark et al, 1987; Zinser et al, 1987; Koenders et al, 1992; Gregory et al, 1993) , cases with visceral metastases and, particularly, liver involvement have been found to have the worst prognosis. However, the multivariate survival analysis clearly showed that the tumour load may also negatively influence the life expectancy, independently from the dominant site of disease.
The overall disease extent was assessed, in the present study, using the method firstly described by Swenerton et al (1979) and subsequently updated by Colomer et al (1989) , who introduced information determined from the CT scan. Using the same criteria, we observed at least three patient subsets with divergent life expectancies, confirming the availability of this method for the overall tumour load determination.
The prognostic significance of CA 15-3 (Berruti et al, 1994 ) may be because of its relationship with disease extent, or, alternatively, the mucinous marker may reflect the state of cell differentiation and aggressiveness of the tumour (Saccani Jotti and Bombardieri, 1990) . The increase of either marker levels or the frequency of supranormal values with the increase of tumour load suggest that CA 15-3 values reflect the number of breast cancer cells secreting the marker and its prognostic role is because of the strict relationship with disease extent. This hypothesis is supported by the finding that the prognostic influence of the marker is not confirmed in the multivariate Cox model in which disease extent and CA 15-3 were concomitantly tested.
The assessment of tumour load is time-consuming and often difficult in practice. In this study, in fact, disease extent was not evaluable in about 25% of the patients: 39 (12%) because of insufficient information and 41 (13%) because of non-measurable disease (pleural effusion, lymphangitis or ascites). The relationship between marker levels and disease extent supports the use of CA 15-3 in this respect, allowing a strict monitoring of tumour variation as a consequence of treatment administration (Tondini et al, 1988; Safi et al, 1989; Robertson et al, 1991) . It should be noted, however, that the circulating marker values in patients with the same disease extent score were not homogeneous. We do not think that clearance mechanisms accounted for this discrepancy as patients with liver or renal impairment were not included. The recent finding of a spread presence of antibody against mucines in sera of patients with breast cancer may offer a possible explanation for the cases with high disease extent and low CA 15-3 levels (Gourevitch et al, 1995) .
The usefulness of serial CA 15-3 evaluation in the follow-up of disease-free patients after mastectomy is debatable, mainly because it was found to be unable to detect the early stages of recurrence of disease. However, the relationship between CA 15-3 positivity at first relapse of disease and overall survival suggests that the marker could selectively detect patients with poor prognosis who may benefit from an early aggressive treatment.
